Cargando…
Anti-inflammatory treatments for stroke: from bench to bedside
So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of bo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066814/ https://www.ncbi.nlm.nih.gov/pubmed/30083232 http://dx.doi.org/10.1177/1756286418789854 |
_version_ | 1783343037303226368 |
---|---|
author | Drieu, Antoine Levard, Damien Vivien, Denis Rubio, Marina |
author_facet | Drieu, Antoine Levard, Damien Vivien, Denis Rubio, Marina |
author_sort | Drieu, Antoine |
collection | PubMed |
description | So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators. |
format | Online Article Text |
id | pubmed-6066814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60668142018-08-06 Anti-inflammatory treatments for stroke: from bench to bedside Drieu, Antoine Levard, Damien Vivien, Denis Rubio, Marina Ther Adv Neurol Disord Review So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators. SAGE Publications 2018-07-30 /pmc/articles/PMC6066814/ /pubmed/30083232 http://dx.doi.org/10.1177/1756286418789854 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Drieu, Antoine Levard, Damien Vivien, Denis Rubio, Marina Anti-inflammatory treatments for stroke: from bench to bedside |
title | Anti-inflammatory treatments for stroke: from bench to
bedside |
title_full | Anti-inflammatory treatments for stroke: from bench to
bedside |
title_fullStr | Anti-inflammatory treatments for stroke: from bench to
bedside |
title_full_unstemmed | Anti-inflammatory treatments for stroke: from bench to
bedside |
title_short | Anti-inflammatory treatments for stroke: from bench to
bedside |
title_sort | anti-inflammatory treatments for stroke: from bench to
bedside |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066814/ https://www.ncbi.nlm.nih.gov/pubmed/30083232 http://dx.doi.org/10.1177/1756286418789854 |
work_keys_str_mv | AT drieuantoine antiinflammatorytreatmentsforstrokefrombenchtobedside AT levarddamien antiinflammatorytreatmentsforstrokefrombenchtobedside AT viviendenis antiinflammatorytreatmentsforstrokefrombenchtobedside AT rubiomarina antiinflammatorytreatmentsforstrokefrombenchtobedside |